브랜드 제네릭 시장 규모 조사 : 제품 유형별, 투여 경로별, 적응증별, 유통 채널별, 지역별 예측(2022-2032년)

Global Branded Generics Market is valued at approximately USD 432.30 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 14.66% over the forecast period 2024-2032. Branded generics are medications bioequivalent to original innovator drugs and are marketed under a different brand name by another company post-patent expiration. These drugs, formulated using the same active pharmaceutical ingredients (APIs) as the innovator product, must meet similar regulatory requirements for manufacturing, safety, and efficacy standards. The primary growth drivers for the branded generics market include rising consumer awareness of accessible treatment options, increasing healthcare expenditure, and numerous patent expirations on blockbuster drugs.

Furthermore, the significant adoption of value-added branded generics, due to their additional benefits such as combined multiple active ingredients or innovative dosage forms, is driving market growth. For example, Benitek A (Olmesatran in combination with Amlodipine), Nifedical (nifedipine), and Digitek (digoxin) are some value-added products designed to enhance therapeutic effects or reduce side effects. However, the market faces challenges such as stringent regulatory requirements for drug approval and quality control, as well as price erosion due to intense competition among manufacturers.

The route of administration plays a crucial role in the market dynamics, with oral administration being the most common and preferred method due to its convenience and non-invasive nature. Parenteral and topical routes are also significant, particularly for drugs that require quick relief or localized delivery. The indication segment reveals a burgeoning utilization of branded generics for gastrointestinal and neurological diseases, with increasing demand for cost-effective therapies in these areas.

The key regions considered for the global Branded Generics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Branded Generics Market in terms of revenue. The market growth in the region is being attributed to factors including robust healthcare infrastructure and high per capita spending on pharmaceuticals. Also, increasing healthcare expenditure and favorable pricing policies drive market demand. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising R&D activities, supportive government initiatives, and increasing demand for trade generics.

Major market players included in this report are:

• Abbott Laboratories
• Ajanta Pharma Ltd.
• Alkem Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• Apotex Inc.
• Aspen Pharmacare Holdings Limited
• AstraZeneca PLC
• Aurobindo Pharma Limited
• Bausch Health Companies Inc.
• Bristol-Myers Squibb Company
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Endo International PLC
• Eris Lifesciences Limited
• Fresenius Kabi AG

The detailed segments and sub-segment of the market are explained below:

By Product:

• Trade Named Generics
• Value-Added

By Drug Type:

• Alkylating Agents
• Anti-depressants
• Anti-epileptics
• Anti-hypertensive
• Anti-psychotics
• Antimetabolites
• Hormones
• Lipid Lowering Drugs

By Route of Administration:

• Oral
• Parenteral
• Topical

By Indication:

• Acute & Chronic Pain
• Cardiovascular Diseases
• Dermatological Diseases
• Gastrointestinal Diseases
• Neurological Diseases
• Oncology

By Distribution Channel:

• Offline
• Online

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Branded Generics Market Executive Summary

• 1.1. Global Branded Generics Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Product
  • 1.3.2. By Drug Type
  • 1.3.3. By Route of Administration
  • 1.3.4. By Indication
  • 1.3.5. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Branded Generics Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Branded Generics Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Increasing Consumer Awareness
  • 3.1.2. Rising Healthcare Expenditure
  • 3.1.3. Increasing Patent Expirations
• 3.2. Market Challenges
  • 3.2.1. Stringent Regulatory Requirements
  • 3.2.2. Price Erosion Due to Competition
• 3.3. Market Opportunities
  • 3.3.1. Advancements in Pharmaceutical Research
  • 3.3.2. Development of Bioequivalent Products

Chapter 4. Global Branded Generics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Branded Generics Market Size & Forecasts by Product (2022-2032)

• 5.1. Segment Dashboard
• 5.2. Global Branded Generics Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Trade Named Generics
  • 5.2.2. Value-Added

Chapter 6. Global Branded Generics Market Size & Forecasts by Drug Type (2022-2032)

• 6.1. Segment Dashboard
• 6.2. Global Branded Generics Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Alkylating Agents
  • 6.2.2. Anti-depressants
  • 6.2.3. Anti-epileptics
  • 6.2.4. Anti-hypertensive
  • 6.2.5. Anti-psychotics
  • 6.2.6. Antimetabolites
  • 6.2.7. Hormones
  • 6.2.8. Lipid Lowering Drugs

Chapter 7. Global Branded Generics Market Size & Forecasts by Route of Administration (2022-2032)

• 7.1. Segment Dashboard
• 7.2. Global Branded Generics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Oral
  • 7.2.2. Parenteral
  • 7.2.3. Topical

Chapter 8. Global Branded Generics Market Size & Forecasts by Indication (2022-2032)

• 8.1. Segment Dashboard
• 8.2. Global Branded Generics Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 8.2.1. Acute & Chronic Pain
  • 8.2.2. Cardiovascular Diseases
  • 8.2.3. Dermatological Diseases
  • 8.2.4. Gastrointestinal Diseases
  • 8.2.5. Neurological Diseases
  • 8.2.6. Oncology

Chapter 9. Global Branded Generics Market Size & Forecasts by Distribution Channel (2022-2032)

• 9.1. Segment Dashboard
• 9.2. Global Branded Generics Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 9.2.1. Offline
  • 9.2.2. Online

Chapter 10. Global Branded Generics Market Size & Forecasts by Region (2022-2032)

• 10.1. North America Branded Generics Market
  • 10.1.1. U.S. Branded Generics Market
    • 10.1.1.1. Product breakdown size & forecasts, 2022-2032
    • 10.1.1.2. Drug Type breakdown size & forecasts, 2022-2032
    • 10.1.1.3. Route of Administration breakdown size & forecasts, 2022-2032
    • 10.1.1.4. Indication breakdown size & forecasts, 2022-2032
    • 10.1.1.5. Distribution Channel breakdown size & forecasts, 2022-2032
  • 10.1.2. Canada Branded Generics Market
• 10.2. Europe Branded Generics Market
  • 10.2.1. U.K. Branded Generics Market
  • 10.2.2. Germany Branded Generics Market
  • 10.2.3. France Branded Generics Market
  • 10.2.4. Spain Branded Generics Market
  • 10.2.5. Italy Branded Generics Market
  • 10.2.6. Rest of Europe Branded Generics Market
• 10.3. Asia-Pacific Branded Generics Market
  • 10.3.1. China Branded Generics Market
  • 10.3.2. India Branded Generics Market
  • 10.3.3. Japan Branded Generics Market
  • 10.3.4. Australia Branded Generics Market
  • 10.3.5. South Korea Branded Generics Market
  • 10.3.6. Rest of Asia-Pacific Branded Generics Market
• 10.4. Latin America Branded Generics Market
  • 10.4.1. Brazil Branded Generics Market
  • 10.4.2. Mexico Branded Generics Market
  • 10.4.3. Rest of Latin America Branded Generics Market
• 10.5. Middle East & Africa Branded Generics Market
  • 10.5.1. Saudi Arabia Branded Generics Market
  • 10.5.2. South Africa Branded Generics Market
  • 10.5.3. Rest of Middle East & Africa Branded Generics Market

Chapter 11. Competitive Intelligence

• 11.1. Key Company SWOT Analysis
• 11.2. Top Market Strategies
• 11.3. Company Profiles
  • 11.3.1. Abbott Laboratories
    • 11.3.1.1. Key Information
    • 11.3.1.2. Overview
    • 11.3.1.3. Financial (Subject to Data Availability)
    • 11.3.1.4. Product Summary
    • 11.3.1.5. Market Strategies
  • 11.3.2. Ajanta Pharma Ltd.
  • 11.3.3. Alkem Laboratories Ltd.
  • 11.3.4. Amneal Pharmaceuticals LLC
  • 11.3.5. Apotex Inc.
  • 11.3.6. Aspen Pharmacare Holdings Limited
  • 11.3.7. AstraZeneca PLC
  • 11.3.8. Aurobindo Pharma Limited
  • 11.3.9. Bausch Health Companies Inc.
  • 11.3.10. Bristol-Myers Squibb Company
  • 11.3.11. Cipla Limited
  • 11.3.12. Dr. Reddy's Laboratories Ltd.
  • 11.3.13. Endo International PLC
  • 11.3.14. Eris Lifesciences Limited
  • 11.3.15. Fresenius Kabi AG

Chapter 12. Research Process

• 12.1. Research Process
  • 12.1.1. Data Mining
  • 12.1.2. Analysis
  • 12.1.3. Market Estimation
  • 12.1.4. Validation
  • 12.1.5. Publishing
• 12.2. Research Attributes